NeoRx cancer news

NERX restructured and will reduce its headcount by 42% to 29 employees to focus on its picoplatin ( NX 473) IV chemotherapeutic. NERX will discontinue development of its Skeletal Targeted Radiotherapy (STR) program, which was in Phase III testing for multiple myeloma (MM) and Phase I testing for breast cancer. The decision was based in part on FDA's request to extend the endpoints, increase the patient number and lengthen the follow-up period of the Phase III trial. ...